Japan Human Rotavirus Vaccine Market Report 2022 to 2030

Japan Human Rotavirus Vaccine Market Analysis

$ 3999

Japan human rotavirus vaccine market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The increasing global supply of goods to comply with and meet the demands of immunisation strategies to eradicate endemic diseases is one of the major reasons boosting market expansion. Globally, there is more government control to ensure that everyone has access to low- or no-cost immunizations. All these factors will drive the growth of human rotavirus vaccine market. Some of the key players in this market are GlaxoSmithKline plc. (UK), Sanofi (France), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Emergent BioSolutions, Inc. (US), CSL Limited (Australia), Inovio Pharmaceuticals, Inc. (US), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan).

ID: IN10JPPH305 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Aneri Parekh

Buy Now

Japan Human Rotavirus Vaccine Market Analysis Summary

Japan Human Rotavirus Vaccine Market is valued at around $473.2 Mn in 2022 and is projected to reach $1113.4 Mn by 2030, exhibiting a CAGR of 11.29% during the forecast period 2023-2030.

Children under the age of five are more vulnerable to the rotavirus. The virus can cause stomach pain in addition to vomiting, fever, and severe watery diarrhoea. Rotavirus infection in children can cause dehydration and hospitalization. The spread of the disease cannot be stopped by excellent hygiene practices alone, notwithstanding their importance. The rotavirus vaccine is your child's best line of defence against rotavirus illness. When given the vaccine, nine out of ten kids will be mostly protected from severe rotavirus illness. Regardless of how severe it is, rotavirus illness will not affect 7 out of 10 children.

The increasing global supply of goods to comply with and meet the demands of immunization strategies to eradicate endemic diseases is one of the major reasons boosting market expansion. Making sure that everyone has access to cheap immunizations is a top concern for government agencies, healthcare facilities, and pharmaceutical companies. Globally, there is more government control to ensure that everyone has access to low- or no-cost immunizations. All these factors will drive the growth of human rotavirus vaccine market. Some of the key players in this market are GlaxoSmithKline plc. (UK), Sanofi (France), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Emergent BioSolutions, Inc. (US), CSL Limited (Australia), Inovio Pharmaceuticals, Inc. (US), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan).

Market Dynamics

Market Growth Drivers

It is anticipated that the market for human rotavirus vaccinations will expand during the course of the forecast period, which will conclude in 2028, as a result of a number of important factors. The market for the human rotavirus vaccine is affected by two factors: greater development and a rise in the number of persons with lesser immunity. The current market will also grow over period, as public awareness of the industry is also growing. Along with the general population and the quantity of live births, the older age group has experienced tremendous growth. Due to all of these factors, the market for human rotavirus vaccinations is expanding.

Market Restraints

The market for human rotavirus therapeutics is benefiting from a large drop in healthcare expenses that is being experienced in the majority of developed countries. One of the key things impeding the market for human rotavirus vaccinations is this. The market for human rotavirus vaccinations is anticipated to be constrained by rising vaccine costs. The side effects and negative reactions to vaccinations have also increased.

Competitive Landscape

Key Players

GlaxoSmithKline plc. (UK)
Sanofi (France)
Pfizer Inc. (US)
Merck & Co., Inc. (US)
Novartis AG (Switzerland)
Emergent BioSolutions, Inc. (US)
CSL Limited (Australia)
Inovio Pharmaceuticals, Inc. (US)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Human Rotavirus Vaccine Market Segmentation

By Market Type

Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others

By Market Applications

Hospitals and Clinics
Academic and Research centers

By End Users

Demand from paediatricians
Demand from gynecologists
Demand from others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.